T. Rowe Price Investment Management Inc. decreased its holdings in shares of Cabot Co. (NYSE:CBT - Free Report) by 39.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 551,940 shares of the specialty chemicals company's stock after selling 364,956 shares during the quarter. T. Rowe Price Investment Management Inc. owned approximately 1.02% of Cabot worth $50,398,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Norges Bank acquired a new position in Cabot during the 4th quarter valued at approximately $37,961,000. Copeland Capital Management LLC boosted its holdings in shares of Cabot by 21.6% during the fourth quarter. Copeland Capital Management LLC now owns 761,372 shares of the specialty chemicals company's stock valued at $69,521,000 after acquiring an additional 135,119 shares during the period. American Century Companies Inc. grew its position in shares of Cabot by 8.5% during the fourth quarter. American Century Companies Inc. now owns 1,323,347 shares of the specialty chemicals company's stock worth $120,835,000 after acquiring an additional 103,380 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Cabot by 27.1% during the fourth quarter. JPMorgan Chase & Co. now owns 451,513 shares of the specialty chemicals company's stock worth $41,228,000 after acquiring an additional 96,179 shares during the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Cabot by 3,242.5% in the 4th quarter. Marshall Wace LLP now owns 74,338 shares of the specialty chemicals company's stock worth $6,788,000 after acquiring an additional 72,114 shares during the period. Institutional investors own 93.18% of the company's stock.
Analyst Ratings Changes
CBT has been the subject of several recent analyst reports. UBS Group decreased their target price on shares of Cabot from $93.00 to $83.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. JPMorgan Chase & Co. decreased their price target on Cabot from $105.00 to $85.00 and set an "underweight" rating for the company in a research note on Friday, February 21st. Mizuho cut their price objective on shares of Cabot from $122.00 to $110.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. Finally, StockNews.com raised shares of Cabot from a "hold" rating to a "buy" rating in a research note on Thursday, April 17th.
View Our Latest Report on CBT
Cabot Trading Down 0.4 %
Shares of Cabot stock traded down $0.29 on Tuesday, reaching $78.68. 595,516 shares of the company were exchanged, compared to its average volume of 391,623. The company has a current ratio of 2.00, a quick ratio of 1.29 and a debt-to-equity ratio of 0.72. Cabot Co. has a fifty-two week low of $73.63 and a fifty-two week high of $117.46. The firm has a market capitalization of $4.27 billion, a price-to-earnings ratio of 10.45, a price-to-earnings-growth ratio of 0.74 and a beta of 1.04. The stock has a fifty day moving average price of $81.74 and a 200-day moving average price of $93.34.
Cabot (NYSE:CBT - Get Free Report) last announced its earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.74 by $0.02. Cabot had a net margin of 10.60% and a return on equity of 26.79%. On average, analysts expect that Cabot Co. will post 7.57 EPS for the current year.
Cabot Profile
(
Free Report)
Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.
Recommended Stories

Before you consider Cabot, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabot wasn't on the list.
While Cabot currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.